Skip to main content

Table 2 Comparison of liver function and WBC count among groups

From: Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome

Group (Survived No.)

ALT (U/L)

AST (U/L)

Bilirubin (µmol/L)

WBC (109/L)

A (n = 8)

47.4 ± 3.7

141.5 ± 9.3

0.88 ± 0.11

6.0 ± 0.9

B (n = 7)

143.6 ± 11.8*

478.3 ± 18.1*

18.72 ± 1.50*

11.2 ± 0.5*

C (n = 10)

122.3 ± 3.7*

396.3 ± 6.5*#

14.32 ± 3.71*#

10.6 ± 0.8*

D (n = 12 )

64.4 ± 4.5*#

220.3 ± 5.3*#

5.55 ± 3.60*#

8.1 ± 0.2*#

E (n = 13 )

60.2 ± 4.9*#

195.3 ± 3.7*#

5.80 ± 2.60*#

8.3 ± 0.4*#

  1. 注: *P < 0.05, compared to group A; #P < 0.05, compared to group B
  2. Group A: control group; Group B: HSOS model group; Group C: low dose LMWH group; Group D: high dose LMWH group; Group E: defibrotide group
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us